Other languages Teva Pharmaceutical Industries Limited

Equities

TEVA

US8816242098

Market Closed - Nyse Other stock markets 16:00:02 2024-04-26 EDT			5-day change	1st Jan Change
13.81 ^USD	+4.23%		+7.39%	+32.28%

04-22	Vanda Pharmaceuticals Appeal for Patents on Sleep Drug Declined by US Supreme Court	MT
04-19	Alvotech Shares Rise After Signing Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)	04-17
Teva Pharmaceutical Unit Says Late-Stage Trial in China of Ajovy to Prevent Migraine Achieves Primary, Secondary Endpoints	04-11
Teva Confirms Efficacy and Safety of AJOVY for the Prevention of Migraine with Results from Phase 3 Trial in China	04-11
Teva Pharmaceuticals International, mAbxience Sign Licensing Deal for Oncology Biosimilar Candidate	04-04
US Appellate Court Vacates Ruling Maintaining Johnson & Johnson's Schizophrenia Drug Patent; Sends Back for Review	04-01
US Appellate Court Vacates Ruling Maintaining Johnson & Johnson's Schizophrenia Drug Patent; Sends Back for Review	04-01
Teva Pharmaceutical to Get $150 Million From Carlyle Group's Abingworth for Asthma Therapy With Launch Therapeutics	04-01
FDA rechaza aprobación de inyección de Viatris para la esclerosis múltiple	03-11
Teva Pharmaceutical Industries Insider Sold Shares Worth $657,240, According to a Recent SEC Filing	03-07
Teva Pharmaceutical Industries Insider Sold Shares Worth $1,048,119, According to a Recent SEC Filing	03-07
Teva Pharmaceutical Industries Insider Sold Shares Worth $1,352,090, According to a Recent SEC Filing	03-07
Teva Pharmaceutical Industries Insider Sold Shares Worth $414,270, According to a Recent SEC Filing	03-05
Teva Pharmaceutical Industries Insider Sold Shares Worth $1,277,207, According to a Recent SEC Filing	03-05
Teva Pharmaceutical Industries Insider Sold Shares Worth $270,176, According to a Recent SEC Filing	03-01
Alvotech, Teva Say Simlandi Receives US FDA Approval as Interchangeable Humira Biosimilar	02-26
Alcoa : Berkshire Hathaway, Teva... les valeurs à suivre aujourd'hui à Wall Street -	02-26
Exchange-Traded Funds Higher, Equity Futures Lower Pre-Bell Monday Ahead of Data-Packed Week	02-26
Teva Pharmaceutical Industries : attendu en hausse après l'approbation du Simlandi par la FDA	02-26
Teva Pharmaceutical's TEV-'574 Antibody Found to Be Safe in Studies	02-20
Teva Pharm to stay as unified drugmaker, sees big interest in API business, says CEO	02-20

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Teva Pharmaceutical Industries isn't out of the woods yet

February 01, 2024 at 04:41 am

INTERVIEW - Richard Francis, CEO of Teva Pharmaceutical: solid quarter, full-year forecasts raised

August 02, 2023 at 03:19 pm